Determination of Potential Drug-Drug Interactions in Patients Using Quinolone Group Antibiotics
Öz
Aim: The aim of the study was to determine the potential drug drug interactions of patients receiving inpatient treatment in the intensive care unit and infectious diseases ward and using quinolone group antibiotics by using different interaction software programs.
Material and Methods: The prescriptions of 100 patients who received inpatient treatment in infectious diseases service and intensive care unit at Selçuk University Faculty of Medicine Hospital between January 2022 and December 2022 and who were treated with quinolone group antibiotics during treatment were analyzed retrospectively.
Results: Of the patients included in the study, 62 were male and 38 were female. The mean age of men was 65.76 ± 16.22 years, while the mean age of women was 68.63 ± 16.29 years. While Medscape® detected a total of 1776 interactions, this number was 1432 in Lexicomp® and 1693 in Drugs®.While 0.33% of the interactions detected in the Medscape® software program were contraindicated, 3.77% of the interactions were contraindicated in Lexicomp®. Kendall W coefficient 0.94, Chi-Square test 281.12, p <0.001 were found to be statistically significant. The software programs used to detect pDDIs are highly compatible with each other.
Conclusion: High agreement was found between software programs used to detect potential drug-drug interactions. Interaction classifications between software programs are different. Therefore, clinicians may benefit from different software programs.
Anahtar Kelimeler
Kaynakça
- BÜYÜKOKUROĞLU ME, TANYERİ P, KELEŞ R. İlaç-ilaç etkileşimleri konusunda farkındalık. Online Türk Sağlık Bilimleri Dergisi. 2019;4(3):377-91.
- Peng Y, Cheng Z, Xie F. Evaluation of pharmacokinetic drug–drug interactions: a review of the mechanisms, in vitro and in silico approaches. Metabolites. 2021;11(2):75.
- Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 2013;18(7):601-10.
- Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30(5):379-407.
- Pitman SK, Hoang UTP, Wi CH, Alsheikh M, Hiner DA, Percival KM. Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant? Antibiotics (Basel). 2019;8(3).
- Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother. 2006;7(6):639-51.
- Brouwers JR. Drug interactions with quinolone antibacterials. Drug Saf. 1992;7(4):268-81.
- Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. Jama. 2003;289(7):885-8.
- Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-93.
- Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt). 2013;14(1):73-156.